Together, we’ll achieve more.

The highly targeted SureSeq Myeloid MRD Panel enables the detection of 13 key AML MRD-associated biomarkers to provide a more comprehensive picture of the current AML status of your samples. Key targets include very large, ultra-low frequency FLT3-ITDs (even up to 300 bp) that are traditionally challenging to detect. The streamlined, guideline-driven panel content expands on OGT customer’s MRD detection capabilities to deliver a better understanding of the current AML status, and ensures genomic insights are not missed.

Improving upon existing SureSeq technology, this latest SureSeq NGS panel unlocks more efficient and expansive genetic profiling for CLL samples. The figure (right) illustrates the panel's uniformity and high depth of coverage, allowing the confident detection of [A] a SF3B1 exon 15 hotspot variant Lys700Glu with 4.8% allele frequency and [B] a TP53 exon 4 frameshift deletion (TP53 c.124del) with frequency 38.9%.

The CDKN2A Probe covers CDKN2A (P16) gene and flanking regions, and is labeled in gold. The Centromere 17 Probe covers the chromosome 17 centromere (D17Z1) region and is labeled in aqua. The Centromere 3 Probe covers the chromosome 3 centromere (D3Z1) region and is labeled in red. The Centromere 7 Probe covers the chromosome 7 centromere (D7Z1) region and is labeled in green.